Tempus AI (NASDAQ:TEM) experienced a sharp decline over the past week, with shares falling 18.6% to close at $42.69 on Friday. The stock dropped 7.2% in the final session alone, as market participants focused on the mechanics of the company's planned acquisition of Personalis (NASDAQ:PSNL).
The current price sits below both reference points outlined in the deal's structure. Under the maximum exchange ratio of 0.3356, each Personalis share would be valued at approximately $14.33 based on Friday's closing price, which is 11.8% below the announced $16.25 per share value. The deal's official benchmark relies on the volume-weighted average price (VWAP) of Tempus shares over the 15 trading days before closing.
Personalis has the option to terminate the agreement only if the pre-closing VWAP falls below $46.00. Friday's spot price of $42.69 is 7.2% below that threshold, though the termination trigger is based on the VWAP, not the spot price. This nuance has become a focal point for investors evaluating the transaction's likelihood of completion.
Tempus retains the flexibility to adjust the consideration by choosing to pay up to 50% in cash, a decision that rests solely with the company. The cash could come from existing resources or additional debt. Based on Friday's levels, a theoretical 50% cash option would yield a blended value of approximately $15.29 per Personalis share, still 5.9% below the stated price.
Personalis shares ended the session at $11.78, reflecting a 21.6% spread compared to the all-stock equivalent of $14.33, before accounting for approval and closing risks. The spread highlights market skepticism about the deal's final terms or its completion.
The broader market also declined, with the Nasdaq Composite falling 0.6%. Among Tempus's peers, Guardant Health (NASDAQ:GH) dropped 1.9%, Natera (NASDAQ:NTRA) eased 1.0%, and Personalis slipped 3.7%. Guggenheim analyst Subbu Nambi attributed the early market response to the stock-based financing structure, as reported by Reuters.
Beyond the merger dynamics, Tempus's operational outlook remains a key consideration. The company has held exclusive distribution rights for Personalis's NeXT Personal residual-disease assay since 2023. During the first quarter, Tempus conducted approximately 6,500 NeXT Personal tests, with volume climbing to about 9,000 in the second quarter, a 38% sequential increase. Currently, only 10% of its sales team focuses on residual-disease products.
Personalis reported preliminary second-quarter revenue of $22.4 million, with clinical test volume increasing 33% quarter-over-quarter to 10,384. Tempus CEO Eric Lefkofsky cited improved reimbursement and Personalis's financial progress as factors driving the acquisition, stating, "We felt now was the right time to pursue a strategic acquisition."
Tempus is scheduled to report its second-quarter results on Thursday, with a conference call at 4:30 p.m. EDT. The initial Zacks consensus estimate projects revenue of $381.6 million, representing a 21.3% increase. Management has committed to providing additional details about Personalis's financial impact during the call. The company continues to target positive EBITDA and free cash flow by 2027.
Key risks remain: the deal requires approval from Personalis shareholders and regulatory clearance. If the pre-close VWAP falls below $46, Personalis may terminate the agreement. The use of debt would increase leverage, while issuing stock would dilute ownership for Tempus stakeholders. Thursday's earnings call is expected to address both the company's growth trajectory and how it plans to protect its acquisition currency.
